Q4: 2026-04-14 Earnings Summary
EPS of -$0.60 misses by $0.20
| Revenue of $33.63M beats by $1.62M
Gloo Holdings, Inc. (GLOO) Q3 2025 Earnings Call December 17, 2025 5:00 PM EST
Company Participants
Oliver Roll – Chief Marketing & Communications Officer
Scott Beck – Co-Founder, President, CEO & Director
Paul Seamon – Chief Financial Officer
Patrick Gelsinger – Executive Chairman & Head of Technology
Conference Call Participants
Richard Baldry – ROTH Capital Partners, LLC, Research Division
Yun Suk Kim – Loop Capital Markets LLC, Research Division
Jason Kreyer – Craig-Hallum Capital Group LLC, Research Division
Daniel Kurnos – The Benchmark Company, LLC, Research Division
Eric Wold – Texas Capital Securities, Research Division
Ryan Meyers – Lake Street Capital Markets, LLC, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Gloo Fiscal Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to turn the conference over to Oliver Roll, Chief Marketing and Communications Officer. Please go ahead.
Oliver Roll
Chief Marketing & Communications Officer
Thank you, operator. And thank you to all of you for joining our fiscal third quarter 2025 earnings conference call. We will be discussing Gloo’s performance for the third quarter ended October 31 2025, as well as providing guidance for the fiscal fourth quarter 2025 and fiscal year 2026.
Joining me on today’s call are CEO and Co-Founder, Scott Beck, and CFO, Paul Seamon. Our Board Chair and Head of Technology, Pat Gelsinger, will also join the Q&A session.
Before we begin, please be reminded that this call will contain forward-looking statements which are based on Gloo’s current expectations, but which are subject to risks and uncertainties relating to future events and/or the future financial performance of Gloo. Actual results could differ materially from those anticipated in these forward-looking statements. A discussion of some of the risks that could cause actual results to differ materially from
